TY - JOUR
T1 - Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections
AU - Matlock, Aaron
AU - Garcia, Joshua Allan
AU - Moussavi, Kayvan
AU - Long, Brit
AU - Liang, Stephen Yuan Tung
N1 - Publisher Copyright:
© 2021, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
PY - 2021/11
Y1 - 2021/11
N2 - Antimicrobial resistance is a growing threat to public health and an increasingly common problem for acute care physicians to confront. Several novel antibiotics have been approved in the past decade to combat these infections; however, physicians may be unfamiliar with how to appropriately utilize them. The purpose of this review is to evaluate novel antibiotics active against resistant gram-negative bacteria and highlight clinical information regarding their use in the acute care setting. This review focuses on novel antibiotics useful in the treatment of infections caused by resistant gram-negative organisms that may be seen in the acute care setting. These novel antibiotics include ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilistatin/relebactam, cefiderocol, plazomicin, eravacycline, and omadacycline. Acute care physicians should be familiar with these novel antibiotics so they can utilize them appropriately.
AB - Antimicrobial resistance is a growing threat to public health and an increasingly common problem for acute care physicians to confront. Several novel antibiotics have been approved in the past decade to combat these infections; however, physicians may be unfamiliar with how to appropriately utilize them. The purpose of this review is to evaluate novel antibiotics active against resistant gram-negative bacteria and highlight clinical information regarding their use in the acute care setting. This review focuses on novel antibiotics useful in the treatment of infections caused by resistant gram-negative organisms that may be seen in the acute care setting. These novel antibiotics include ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilistatin/relebactam, cefiderocol, plazomicin, eravacycline, and omadacycline. Acute care physicians should be familiar with these novel antibiotics so they can utilize them appropriately.
KW - Antibiotics
KW - Multidrug-resistant
KW - Novel
KW - Resistance
UR - http://www.scopus.com/inward/record.url?scp=85105531026&partnerID=8YFLogxK
U2 - 10.1007/s11739-021-02749-1
DO - 10.1007/s11739-021-02749-1
M3 - Review article
C2 - 33956311
AN - SCOPUS:85105531026
SN - 1828-0447
VL - 16
SP - 2231
EP - 2241
JO - Internal and Emergency Medicine
JF - Internal and Emergency Medicine
IS - 8
ER -